Cotinga Pharmaceuticals Current ratio
Cos'è Current ratio di Cotinga Pharmaceuticals?
Current ratio di Cotinga Pharmaceuticals, Inc. è 0.05
Qual è la definizione di Current ratio?
Il rapporto corrente è un rapporto di liquidità che misura se una società dispone o meno di risorse sufficienti per soddisfare i suoi obblighi a breve termine.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio di aziende nel Health Care settore su TSXV rispetto a Cotinga Pharmaceuticals
Cosa fa Cotinga Pharmaceuticals?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Aziende con current ratio simili a Cotinga Pharmaceuticals
- Classic Minerals ha Current ratio di 0.05
- Engineer Gold Mines ha Current ratio di 0.05
- Rigel Resource Acquisition ha Current ratio di 0.05
- Gas2Grid ha Current ratio di 0.05
- Cresval Capital ha Current ratio di 0.05
- Transforma Resources Corporatio ha Current ratio di 0.05
- Cotinga Pharmaceuticals ha Current ratio di 0.05
- Ackrell SPAC Partners I Co ha Current ratio di 0.05
- First Bank (NJ) ha Current ratio di 0.05
- International Metals Mining Cor ha Current ratio di 0.05
- Melcor Real Estate Investment Trust ha Current ratio di 0.05
- Horizon Acquisition II ha Current ratio di 0.05
- EJF Investments ha Current ratio di 0.05